

分類廣告價目表

CLASSIFIED AD. RATE

週數 Week	一週	二週	三週	一月
格數 Size	1 wk	2 wks	3 wks	1 mon
1 格 (1unit)	\$45	\$80	\$105	\$125
2 格 (2units)	\$90	\$160	\$210	\$250
3 格 (3units)	\$135	\$240	\$315	\$375
4 格 (4units)	\$180	\$320	\$420	\$500

EFFECTIVE: 從2009年11月1日起實施

Place Your AD

一通電話, 萬事OK

By phone, Fax, Email or in person: 電話, 傳真, 電郵, 上網或登門刊登

Call(電話服務專線): 281-498-4310

Fax (傳真): 832-399-1355

Email(電郵): cla@scdaily.com

Wechat(微信): AD7133021553

Click(上網): www.scdaily.com

Stop by(登門): 11122 Bellaire Blvd Houston TX 77072

Business Hours:

Monday-Friday:

8:00am-4:00pm

上班時間:

週一至週五:

上午八時至下午四時

美南新聞分類廣告 公告欄

主頁 scdaily.com 下方美南廣告 AD

是最受歡迎的 招工/買賣/宣傳 最佳平台

www.scdaily.com/cia/ClaAD.pdf

只要您已刊登美南新聞分類廣告

即可享有刊登一次『10元』的特價活動

請微信: AD7133021553

或致電: 281-498-4310

100

Restaurant Hiring

餐館服務

*糖城中餐館

『新僱』誠請

有經驗企僱多名

意者請電:

832-955-6957

832-814-3029

*糖城餐館請人

Mamak Malaysian Restaurant. 糖城店,

誠聘企台. 新店剛

開張, 新手可以培訓.

環境好, 小費高. 電:

346-874-7913

(每週二公休)

*外賣店請人

近中國城

誠請全工送外賣

懂英文.

有意者請電

281-568-8788

糖城翠苑中餐館

誠請 企台/收銀

全職/兼職

小費好

有意者請電:

832-606-3731

*誠聘(中國城)

●LVN / RN (PT)

●Office Assistant (PT)

●司機 ●清潔半工

●廚房幫工打雜

周一到周五

電: 281-781-9389

未接請短信稍後再覆

*長樂活動中心

誠聘廚房助理

意者請電:

281-208-7709

713-884-5612

*餐館請炒鍋

路州 Shreveport

中餐堂吃店, 誠請

炒鍋和企台。

意者請電:

832-819-8111

(無人接聽可短信)

*高級堂食餐館

I-10 近 Inker St

廚部: 熟手執碼幫炒

樓面: 懂英文有經驗

新金可議,

意者可電:

832-875-1225

Woodlands 中餐館, 薪優

誠請 全工半工均可(提供吃住)

●企台 ●廚房打雜

●油包 ●炒鍋

意者請電: 936-443-2523

新皇宮點心海鮮酒樓 (ChinaBear)

『新僱』全方位誠聘:

經理, 企枱, 收銀, 帶位, 廚房師傅,

點心師傅, 炒鍋, 抓碼, 油鍋, 打雜等等...

意者請電或親臨面談:

281-240-8383 713-303-8998

12755 Southwest Fwy, Stafford TX 77477

珍寶海鮮城 誠聘

點心師傅、點心熟籠、點心幫手

推車、企枱、傳餐。

需少許英文, 全工或半工均可

做滿三個月後, 公司提供 Bonus 獎勵金

請電: 281-988-8898 或親臨面談

11215 Bellaire Blvd, Houston, TX 77072

*餐館請人

近中國城,

誠請熟手炒鍋,

需報稅.

意者請電:

713-826-2265

中餐館新請人

位 Westheimer 近 610

●周二周三全天下送員

有英語能力, 小費特好

●周末全天服務生:

獨立工作能力强,

留言/訊息 必必回復

832-677-0288

*糖城餐館, 薪優

堂吃外賣店, 誠請

●企台 ●廚房抓碼

意者請電:

281-313-3300

另日餐請企枱

646-243-5660

*Buffet 店請人

距中國城 8 分鐘

Buffet 店

誠請 全工 / 半工

熟手企台, 帶位

意者請電:

713-789-0845

*餐館請人

誠招外賣員

位 Spring,

249 與 99 交界

聯系: 林先生

832-310-0739

中餐館請人

誠聘半工外送員

有經驗, 要報稅

離中國城 15 分鐘

4670 Beechnut

意者請電:

713-307-2882

Pearland 餐館

和順順堂吃外賣店

『新僱』誠聘

全工 & 半工收銀和企枱

半工或全工外送員

電 832-768-9888

微信 weijiang7788

中國城中餐館

『高薪』聘請

廣東炒鍋

意者請電:

281-210-8392

黃師傅

Mall 內快餐

●經理助理:

●收銀: (\$14 起薪)

會英語, 報稅.

Houston & Dallas 區

意者請電:

214-924-8009

餐館請人, 薪優

誠聘炒鍋, 打雜

909 Southmore Ave

Pasadena, TX 77502

有意者請電:

713-818-0335

餐館請人

Restaurant Hiring

美式中餐館

Downtown 地區

薪優, 誠招炒鍋,

廚房關係簡單

有意請電至:

713-835-1705

如未接, 請短信留言

餐館請人

位於西北區

誠聘企枱, 炒鍋,

半工外送員.

有意者聯系:

281-966-5342

美式中餐館

誠請全工或半工

收銀接電話

底薪加小費

意者請電:

832-782-8237

粵菜餐館, 薪優

東禾酒家請人

中國城, 敦煌廣場內

誠請炒鍋和企枱

抓碼和油爐

意者請電:

713-981-8803

中餐外賣店

位於 45 號南

薪優, 誠請

●幫炒 (能炒雙飛)

●打雜兼包外賣

提供吃住. 請電:

713-614-3873

金山餐館請人

位 Downtown 誠請

●企枱, 拋鍋, 抓碼

~以上薪水好~

意者請電: 阿泰

916-529-7337

2001 Jefferson

Houston, TX 77003

中餐館請人

位 290 / 8 號附近

招全職/兼職

收銀, 炒鍋, 油鍋, 打雜

意者請電:

832-623-4949

832-773-2913

堂吃外賣店

誠請可接電話企枱,

店不忙, 小費好.

加時薪,

離糖城 15-20 分鐘.

半職/全職皆可

意者請聯絡:

626-592-5535

中國城悅來餐館

誠請有經驗炒鍋

全工/半工均可

有意者請電:

281-683-6368

餐館請人

路州 Shreveport

中餐堂吃店, 誠請

炒鍋和企枱

請電/短信:

832-819-8111

(無人接聽可短信)

*餐館請人

新僱, 誠聘

接電話兼收銀員一名

近中國城 10 分鐘車程

聯系電話: 劉先生

832-898-6667

NOW HIRING

North China Restaurant

I-10 & KATY

Now is hiring

Waiter/Waitress

Full time or Part time

Must speak English

713-470-8118

Katy 中餐館

招全 / 半工外送員

高檔區, 小費好,

需要報稅.

意者請電:

281-665-9299

SINH SINH

位中國城, 中國餐廳

誠請炒鍋、打雜

抓碼, 粉麵 及企枱

請下午 3 點後電:

713-459-1501

壽司餐館請人

Restaurant Hiring

二間壽司吧招工

位 Kroger 超市內

●1801 S. Voss

●1505 Wirt Rd.

急需壽司師父及幫手

全工/半工均可.

『新僱』意者請電:

832-638-3640

*HEB 超市內壽司吧請人

HEB, Kroger Sushi Roll Available People Priority

(Training Available) 10 mins from Pearland

Medical Center / Hwy-288 / Rice University

Address: 6055 South Freeway, Houston, TX

Please call: 832-808-0206

誠請全工/半工壽司師傅及廚房幫手,

懂少許英文即可, 近醫學中心及 Rice 大學

壽司餐館請人

Restaurant Hiring

糖城 HEB 壽司吧

誠招壽司助手

有無經驗均可

意者請電:

832-213-7345

壽司吧急聘

The Sushi Bar is Hiring

We are in urgent need

of Part-time Sushi

Helper in Kroger.

9325 Katy Fwy,

Houston, TX 77024.

281-520-6774 (英)

713-299-4129 (中)

分類廣告專頁

日本餐館請經理

Missouri City 近 Sugar Land,

誠請全職/半職經理.

需有經驗, 說英語,

做事認真負責能報稅,

薪資面議.

有意向請聯系:

912-381-5292

346-303-3218

Qin Dynasty

城中國中日餐館,

誠請 半工外送員,

熟悉醫療中心, 英文流利

半工經驗企枱, 英文流利

懂酒水, 需報稅.

電: 713-660-8386

3-5 親臨: 5115 Buffalo

Speedway #900

*大型中日餐館

位西北區, 誠請

全工包卷師傅,

炒鍋, 幫炒.

包住宿(有獨立房間)

有意者請電:

281-851-5858

KATY 日餐

誠請 ●企枱

●Sushi Man

●廚房師傅

意者請電或

短訊(無人接聽時)

832-232-1001

中日餐館, 薪優誠聘 [奧斯汀]

●熟手炒鍋師傅(Cook)

●熟手油鍋 (Fryer)

●Sushi Chef 壽司師傅

●Kitchen Helper 幫廚

~~~ 住宿環境佳, 交通方便~~~

有意者請電: 512-639-9599

200

餐館租售

Restaurant for sale

美式中餐轉讓

外賣堂吃賺錢老餐館

西北白人區 Kroger 超

市旁, 離中國城 30 分鐘

房租便宜,

因缺人手, 忍痛轉讓

意者請洽: 非誠勿擾

832-830-3906

創業良機

在高銷售額的超市內

Sushi Bar 出售

東主退休, 13 年老店,

月營業額 3 萬以上

意者請下午 3 點後電

或簡訊, 歡迎看店:

832-660-2521

中國城賺錢餐館

出售

位中國城百佳超市旁

2400 呎, 房租便宜

生意穩定, 設備齊全

歡迎看店議價

281-501-9898

718-864-8551

KATY 中餐館

出讓

生意佳

意者請電:

917-287-6173

\*賺錢餐館出售

疫情期間外賣生意很好

東主退休有意出售.

有粵菜經驗者更佳.

意者請電:

210-396-0650

餐館在聖安東尼奧,

競爭極小。

Kroger 壽司吧

轉讓, 近中國城

易經營, 收入穩定,

年收入五萬以上

售價: \$25,000

位 11565 Hwy-6 S.

Sugar Land, TX 77498

電: 832-664-1410

\*城中賺錢餐館

出售

近 Galleria 區

生意穩定

意者請電:

832-620-2560

中餐館退休轉讓

超過 37 年賺錢老店

位於休斯外圍

連地及生意一併出售

生意穩定, 含設備

因東主退休出售

意者請電: Kathy

936-662-6412

\*賺錢餐館出售

●近 Memorial 高級區中餐館, 設備齊全,

年收入 60 萬, 業主榮休, 僅售 \$79,000.

●位於 Katy 亞洲城餐館, 年收入過百萬,

僅售 \$30 萬, 機會難得, 預購從速.

有意者, 請洽德州地產:

713-988-1668, 832-734-6888 (中文)

中餐旺舖出讓

位於 10 號公路旁,

附近住宅林立, 亦鄰近幾大煉油公司,

客源龐大, 因缺人運作, 忍痛出讓.

有意請聯繫: 李小姐

713-732-8203

外賣店轉讓

鐵板日餐店

位 Woodlands 區

1100 呎, 月租 2200

生意穩定, 設備齊全

詳情請電:

281-948-9968

堂吃外賣兼

小 Buffet 轉讓或租賃

設備齊全,

轉手即可賺錢.

詳情請致電:

210-380-2645

非誠勿擾!

糖城中日堂吃

外賣餐館出售

有酒牌, 6 年老店,

生意穩定

旺季來臨, 即買即賺

347-981-8670

分類廣告專頁

















If you would like to share news or information with our readers, please send the unique stories, business

news organization events, and school news to us including your name and phone number in case more information is needed.

For news and information consideration, please send to News@scdaily.com or contact  
**John Robbins 281-965-6390**  
**Jun Gai 281-498-4310**

**Publisher:** Wea H. Lee  
**President:** Catherine Lee  
**Editor:** John Robbins

**Address:** 11122 Bellaire Blvd., Houston, TX 77072  
**E-mail:** News@scdaily.com



Inside C2

# Southern DAILY

Make Today Different

Southern Daily News is published by Southern News Group Daily

Thursday, December 02 2021|

## Omicron rapidly dominating in South Africa, U.S. reports first case

JOHANNESBURG/WASHINGTON, Dec 1 (Reuters) - Heavily mutated Omicron is rapidly becoming the dominant variant of the coronavirus in South Africa less than four weeks after it was first detected there, and the United States on Wednesday became the latest country to identify an Omicron case within its borders.

The first known U.S. case was a fully vaccinated person in California who returned to the United States from South Africa on Nov. 22 and tested positive seven days later.

The infected person had mild symptoms and was in self-quarantine, Dr. Anthony Fauci, a top U.S. infectious disease official, told reporters at the White House.

Late on Tuesday, airlines in the United States were told to hand over the names of passengers arriving from parts of southern Africa hit by Omicron, according to a U.S. Centers for Disease Control and Prevention letter seen by Reuters.

Key questions remain about the new variant, which has been found in two dozen countries, including Spain, Canada, Britain, Austria and Portugal. The UAE reported its first case on Wednesday, the second Gulf country after Saudi Arabia.

Early indications suggesting Omicron may be markedly more contagious than previous variants have rattled financial markets, fearful that new restrictions could choke off a tentative recovery from the economic ravages of the pandemic.

South Africa's National Institute for Communicable Diseases (NICD) said early epidemiological data suggested Omicron was able to evade some immunity, but that existing vaccines should still protect against severe disease and death.

It said 74% of all the virus genomes it had sequenced last month had been of the new variant, which was first found in a sample taken on Nov. 8 in Gauteng, South Africa's most populous province.

The number of new cases reported in South Africa doubled from Tuesday to Wednesday.

World Health Organization epidemiologist Maria van Kerkhove told a briefing that data on how contagious Omicron was should be available "within days."

BioNTech's CEO said the vaccine it makes in a partnership with Pfizer (PFE.N) was likely to offer strong protection against severe dis-



ease from Omicron.

"The World Health Organization classified Omicron as a "variant of concern," due to the number of mutations that might help it spread or evade antibodies from prior infection or vaccination. The president of the European Union's executive Commission said there was a "race against time" to stave off the new variant while scientists establish how dangerous it is. The EU brought forward the start of its vaccine rollout for five-to-11-year-olds by a week to Dec. 13.

"Prepare for the worst, hope for the best," Ursula von der Leyen told a news conference.

A woman gets vaccinated against the coronavirus disease (COVID-19) through a window outside a doctor's practice, in the district of Friedrichshain, Berlin, Germany December 1, 2021. REUTERS/Annegret Hilse  
She said that full vaccination and a booster shot provided the strongest possible protection, according to scientists - a view echoed by Fauci.

But WHO emergencies director Mike Ryan criticized developed countries pushing booster shots for large parts of their fully vaccinated populations when vulnerable people in many poorer regions had had no vaccination at all.

"There is no evidence that I'm aware of that will suggest that boosting the entire

population is going to necessarily provide any greater protection for otherwise healthy individuals against hospitalization or death," he said.

Britain and the United States have both expanded their booster programs in response to the new variant.

The WHO has noted many times that the coronavirus will keep producing new variants for as long as it is allowed to circulate freely in large unvaccinated populations.

An upsurge in new coronavirus variants and poor access to vaccines in developing countries threaten a full recovery from the COVID-19 pandemic.  
An upsurge in new coronavirus variants and poor access to vaccines in developing countries threaten a full recovery from the COVID-19 pandemic.  
**TRAVEL RESTRICTIONS**

Some 56 countries were reportedly implementing travel measures to guard against Omicron as of Nov. 28, the WHO said.

U.N. Secretary-General Antonio Guterres slammed what he called "travel apartheid."

"Blanket travel bans will not prevent

the international spread and they place a heavy burden on lives and livelihoods," the WHO said, while advising those who were unwell, at risk or 60 years and over and unvaccinated to postpone travel.

The United States has barred nearly all foreigners who have been in one of eight southern African countries.

Hong Kong added Japan, Portugal and Sweden to its travel restrictions. Malaysia temporarily barred travelers from eight African countries and said Britain and the Netherlands could join the list.

Fitch Ratings said it had lowered its global air passenger traffic forecasts for 2021 and 2022.

"It feels a little bit like we are back to where we were a year ago," said Deidre Fulton, a partner at consultancy MIDAS Aviation, at an industry webinar. "And that's not a great prospect for the industry and beyond."

Fauci said it could take two weeks or more to gain insight into how easily the variant spreads from person to person, how severe the disease is that it causes, and whether it can bypass the protections provided by vaccines currently available.

 **高科技快速數位快印來臨!** MEET ALL YOUR PROMOTIONAL NEEDS  
為您提供各類廣告宣傳產品, 設計製作一站式服務! **UNDER ONE ROOF**

**美南印刷 USA PRINTING**  
A Southern Chinese Daily Company



專業設計 ✓ 全彩印刷 ✓ 數碼快印 ✓ 大幅噴繪

TEL: 281-983-8152 (CHINESE) 281-983-8154 (ENGLISH) WE'LL HELP YOU GET THE STAND OUT  
11122 BELLAIRE BLVD., HOUSTON, TX 77072 E-MAIL: JENNIFERITC@GMAIL.COM



# WEA LEE'S GLOBAL NOTES

12/01/2021



**Wea H. Lee**  
**Wealee@scdaily.com**

Chairman of International District Houston Texas

**Publisher Southern Daily Wea H. Lee**

Southern News Group Chairman / CEO  
Chairman of International Trade & Culture Center  
Republic of Guiana Honorary consul at Houston Texas

## New Covid Variant Rises Again



President Biden announced new U.S. travel restrictions from South Africa and seven other countries to contain the threat from the newly detected Omicron Covid-19 variant.

The travel ban alone may offer little comfort to Americans which set

a new travel record on the eve of Thanksgiving Day.

Canadian officials confirmed the country's first two cases of the Omicron variant in Ottawa. Germany and the United Kingdom also confirmed cases within their borders. The UK has mandated

face covering in shops and on public transport.

Dr. Paul Burton of Moderna Corporation said in an interview that we should brace for several weeks of uncertainty as scientists and vaccine manufacturers investigate the

transmissibility of the new variant, the level of illness that causes and whether the antibodies produced in response to the current vaccines will be effective in thwarting it.

Scientists are concerned that the new variant has more than 30 mutations as a part of the virus raising fear that the protection offered by vaccines currently available would not be enough.

administration's biggest challenge may be the ongoing stubborn resistance among the approximately 60 million American adults who remain unvaccinated.

We sincerely want to urge all people to get vaccinated to simply protect yourself and your loved ones.

We also want to urge world leaders to work together to fight against this new threat.

The Biden



**Southern DAILY** Make Today Different

## Editor's Choice



Parents walk away with their kids from the Meijer's parking lot where many students gathered following an active shooter situation at Oxford High School in Oxford, Michigan. Eric Seals-USA TODAY NETWORK



A man takes a picture of one of the ships that have been grounded on the shores of the Marmara Sea after extreme winds drove them off their moorings, in Istanbul's Maltepe district, Turkey. REUTERS/Umit Bektas



A restoration company vehicle sits in a flooded field after rainstorms lashed the western Canadian province, triggering landslides and floods, shutting highways, in Abbotsford, British Columbia, Canada. REUTERS/Jennifer Gauthier



A visitor holds a weapon at the Egyptian stand at Egypt Defence Expo (EDEX), showcasing military systems and hardware, in Cairo, Egypt. REUTERS/Mohamed Abd El Ghany



Ghislaine Maxwell listens as defense attorney Bobbi Sternheim gives her opening statement at the start of Maxwell's trial on charges of sex trafficking, in a courtroom sketch in New York City. REUTERS/Jane Rosenberg



An anti-abortion rights activist holds a baby doll during a protest outside the Supreme Court building, ahead of arguments in the Mississippi abortion rights case Dobbs v. Jackson Women's Health, in Washington. REUTERS/Jonathan Ernst



BUSINESS

COVID-19 In The U.S. Update

CDC Panel Endorses COVID-19 Vaccine Boosters For All Adults



Compiled And Edited By John T. Robbins, Southern Daily Editor

A key outside advisory group to the Centers for Disease Control and Prevention (CDC) has endorsed the use of COVID-19 booster shots for all adults, a one-size-fits-all approach designed to simplify eligibility. If CDC Director Rochelle Walensky signs off on the broader use, as expected, the extra shots will be available immediately to all adults, as long as they are six months past the final dose of a Pfizer or Moderna vaccine, or two months after a Johnson & Johnson dose. The recommendation from the panel comes just hours after the Food and Drug Administration (FDA) authorized both Pfizer and Moderna's booster shots for everyone over the age of 18. Pfizer applied to the FDA earlier this month for an expansion of the emergency authorization for its booster shot to make it available to anyone 18 or older. Moderna announced just this week that it too had asked the FDA to allow its booster to be given to all adults. Boosters for everyone has always been the Biden administration's goal, but until now federal health authorities have stopped short of such a policy, and instead recommended boosters for only specific populations — those over age 65, anyone at high risk because of work or where they live, or those with an underlying medical condition. The primary COVID-19 vaccination continues to provide good protection against severe disease and death, even as effectiveness against milder infection has waned. But cases have been steadily rising across the country, and authorities have said they

want to stave off another winter surge.



The current recommendations, while fairly broad, have caused confusion. While people over the age of 65 are most at risk from waning vaccine immunity, fewer than 40 percent of them have received a booster, according to CDC data. "The current guidelines, though well-intentioned and thoughtful, generate an obstacle to uptake of boosters. In pursuit of precision, they create confusion," Nirav Shah, president of Association of State and Territorial Health Officials, told the panel. The panel did not make a distinction in their recommendation between the two types of mRNA vaccines, despite the potential for increased risk of myocarditis — a type of heart inflammation — in young men after receiving Moderna's vaccine. CDC officials told the panel it's too early to draw conclusions on the risk of myocarditis after the third dose of mRNA vaccines, because teens and younger adults haven't yet been boosted in large enough numbers. Several other countries have discouraged use of the Moderna vaccine in people

younger than 30 because of that risk. **Gottlieb Says He Expects The CDC Will Consider 'Fully Vaccinated' As Including Boosters**



**Former Food and Drug Administration Commissioner Scott Gottlieb** Former Food and Drug Administration Commissioner Scott Gottlieb said on Sunday that he expects the Centers for Disease Control and Prevention (CDC) to consider Americans "fully vaccinated" when they receive a booster shot, adding that recommendations to change it would likely not happen this year. "Should the CDC say you need a booster to be considered fully vaccinated?" "Face the Nation" moderator Margaret Brennan asked Gottlieb on CBS. "I think at some point they're going to, but not this year," Gottlieb answered. "I think eventually this will be considered the three-dose vaccine, but I would be hard pressed to believe CDC is going to make that recommendation any time soon, in part because of this debate about whether or not younger people who are less risk should be receiving that third dose in states where governors are looking to do this, and I think some local communities will do it," he added. Gottlieb was also asked about CDC saying last week that all American adults could get a booster shot while specifically recommending that people over the age of 50 get their boosters.



"I think the reluctant nature by which CDC has been stepping into this debate reflects a broader ambivalence or a broader debate happening in a public health community about whether the vaccines should be used as tools to protect people from bad outcomes from COVID, or whether they should be used as tools to try to end the pandemic and control transmission," Gottlieb said. CDC Director Rochelle Walensky late last week signed off on a recommendation from a CDC advisory panel to broaden el-

igibility of the COVID-19 booster to all American adults. The advisory panel had also recommended that those over the age of 50 should get their booster shot.

**Fauci Hopes COVID-19 Booster Increases Durability To Not Need It Regularly**

President Biden's chief medical adviser Anthony Fauci said on Sunday that he hopes COVID-19 boosters will increase vaccine durability so that "you will not necessarily need it" every six months or year. "We would hope - and this is something that we're looking at very carefully - that that third shot with the mRNA not only boosts you way up but increases the durability so that you will not necessarily need it every six months or a year," Fauci said during "This Week" on ABC.

**President Biden's chief medical adviser Anthony Fauci** "We're hoping it pushes it out more. If it doesn't, and the data show we do need it more often, then we'll do it," he added.

Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky signed off on a CDC advisory panel's recommendation to increase eligibility for booster shots to all American adults. The decision means that all adults who are at least six months out since receiving their second shot of the Pfizer or Moderna vaccines are now able to get their third shot of the COVID-19 vaccine. "Booster shots have demonstrated the ability to safely increase people's protection against infection and severe outcomes and are an important public health tool to strengthen our defenses against the virus as we enter the winter holidays. Based on the compelling evidence, all adults over 18 should now have equitable access to a COVID-19 booster dose," Walensky said in a statement regarding the news. The decision comes only weeks after children as young as 5 years old became eligible to get COVID-19 vaccine, much to the relief of parents and health officials seeking to have their kids inoculated in time for holiday gatherings.



Despite widespread vaccine availability, however, it has not stopped the U.S. from passing the grim milestone last week of recording more COVID-19 deaths in 2021 than last year. (Courtesy thehill.com)

**OSHA Suspends Enforcement Of COVID-19 Vaccine Mandate For Businesses**

The Occupational Safety and Health Administration (OSHA) is suspending enforcement of the Biden administration's COVID-19 vaccine mandate for large private businesses after a federal appeals court upheld a stay on it last week.



OSHA said in a statement published on its website Friday night that while it is confident in its power to protect workers amid the pandemic, it is suspending activities related to the mandate, citing the pending litigation. "The court ordered that OSHA 'take no steps to implement or enforce' the ETS [Emergency Temporary Standard] 'until further court order.'" While OSHA remains confident in its authority to protect workers in emergencies, OSHA has suspended activities related to the implementation and enforcement of the ETS pending future developments in the litigation," OSHA said.

**OSHA** President Biden announced in September that the administration

was rolling out a new rule that would require all private employers with 100 or more employees to mandate vaccines or weekly testing for all personnel, a guideline that has the potential to impact nearly 80 million workers. Earlier this month the administration set Jan. 4 as the deadline for qualifying private employers to start mandating the vaccine or requiring weekly testing. The rule was developed by OSHA.

In a 22-page ruling last week, the 5th U.S. Circuit Court of Appeals wrote that the administration's COVID-19 vaccine and testing mandate was "fatally flawed" and ordered that OSHA not enforce the requirement "pending adequate judicial review" of a motion for a permanent injunction. The court said OSHA should "take no steps to implement or enforce the mandate until further court order." (Courtesy thehill.com)

COMMUNITY

A Daily Pill To Treat COVID-19 Could Be Just Months Away, Scientists Say



**Results of trials on a daily pill to treat COVID-19 could be available within months.(Image/Unsplash/Halacious)**


**Key Point**

- *At least three antivirals for COVID are in clinical trials.*
- *An early trial of 202 participants last Spring showed that molnupiravir rapidly reduced the levels of infectious virus.*
- *Antivirals are already essential treatments for viral infections, including hepatitis C and HIV.*
- *The drugs work by interfering with the virus's ability to replicate in human cells*

Compiled And Edited By John T. Robbins, Southern Daily Editor

Within a day of testing positive for Covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room. When her husband, Joe, 46, fell ill with the virus, too, she really got worried, especially about their five teenagers at home: "I thought, 'I hope to God we don't wind up on ventilators. We have children. Who's going to raise these kids?'" But the Kellys, who live in Seattle, had agreed just after their diagnoses to join a clinical trial at the nearby Fred Hutch cancer research center that's part of an international effort to test an antiviral treatment on the unvaccinated that could halt Covid early in its course. By the next day, the couple were taking four pills, twice a day. Though they weren't told whether they had received an active medication or placebo, within a week, they said, their symptoms were better. Within two weeks, they had recovered. "I don't know if we got the treatment, but I kind of feel like we did," Miranda Kelly said. "To have all these underlying conditions, I felt like the recovery was very

quick." The Kellys have a role in developing what could be the world's next chance to thwart Covid: a short-term regimen of daily pills that can fight the virus early after diagnosis and conceivably prevent symptoms from developing after exposure.



"Oral antivirals have the potential to not only curtail the duration of one's Covid-19 syndrome, but also have the potential to limit transmission to people in your household if you are sick," said Timothy Sheahan, a virologist at the University of North Carolina-Chapel Hill who has helped pioneer these therapies. Antivirals are already essential treatments for other viral infections, including hepatitis C and HIV. One of the best known is Tamiflu, the widely prescribed pill that

can shorten the duration of influenza and reduce the risk of hospitalization if given quickly. The medications, developed to treat and prevent viral infections in people and animals, work differently depending on the type. But they can be engineered to boost the immune system to fight infection, block receptors so viruses can't enter healthy cells, or lower the amount of active virus in the body.

At least three promising antivirals for Covid are being tested in clinical trials, with results expected as soon as late fall or winter, said Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, who is overseeing antiviral development. "I think that we will have answers as to what these pills are capable of within the next several months," Dieffenbach said. The top contender is a medication from Merck and Ridgeback Biotherapeutics called molnupiravir, Dieffenbach said. This is the product being tested in the Kellys' Seattle trial. Two others include a candidate from Pfizer, known as PF-07321332, and AT-527, an antiviral produced by Roche and Atea Pharmaceuticals.



They work by interfering with the virus's ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can't reproduce. That, in turn, reduces the patient's viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death. So far, only one antiviral drug, remdesivir, has been approved to treat Covid. But it is given intravenously to patients ill enough to be hospitalized, and is not intended for early, widespread use. By contrast, the top contenders under study can be packaged as pills. Sheahan, who also performed preclinical work on remdesivir, led an early study in mice that showed that molnupiravir could prevent early disease caused by SARS-CoV-2, the virus that causes Covid. The formula was discovered at Emory University and later acquired by Ridgeback and Merck.

Clinical trials have followed, including an early trial of 202 participants last spring that showed that molnupiravir rapidly reduced the levels of infectious virus. Merck chief executive Robert Davis said this month that the company expects data from its larger phase 3 trials in the coming weeks, with the potential to seek emergency use authorization from the Food and Drug Administration "before year-end." Pfizer launched a combined phase 2 and 3 trial of its product Sept. 1, and Atea officials said they expect results from phase 2 and phase 3 trials later this year. If the results are positive and emergency use is granted for any product, Dieffenbach said, "distribution could begin quickly." That would mean millions of Americans soon could have access to a daily orally administered medication, ideally a single pill, that could be taken for five to 10 days at the first confirmation of Covid infection.



"When we get there, that's the idea," said Dr. Daniel Griffin, an infectious diseases and immunology expert at Columbia University. "To have this all around the country, so that people get it the same day they get diagnosed." Once sidelined for lack of interest, oral antivirals to treat coronavirus infections are now a subject of fierce competition and funding. In June, the Biden administration announced it had agreed to obtain about 1.7 million treatment courses of Merck's molnupiravir, at a cost of \$1.2 billion, if the product receives emergency authorization or full approval. The same month, the administration said it would invest \$3.2 billion in the Antiviral Program for Pandemics, which aims to develop antivirals for the Covid crisis and beyond, Dieffenbach said. The pandemic kick-started a long-neglected effort to develop potent antiviral treatments for coronaviruses, said Sheahan. Though the original SARS virus in 2003 gave scientists a scare—followed by Middle East respiratory syndrome, or MERS, in 2012—research efforts slowed when those outbreaks did not persist. "The commercial drive to develop any products just went down the tubes," said Sheahan. Widely available antiviral drugs would join the monoclonal antibody therapies

already used to treat and prevent serious illness and hospitalizations caused by Covid. The lab-produced monoclonal antibodies, which mimic the body's natural response to infection, were easier to develop but must be given primarily through intravenous infusions. The federal government is covering the cost of most monoclonal products at \$2,000 a dose. It's still too early to know how the price of antivirals might compare. Like the monoclonal antibodies, antiviral pills would be no substitute for vaccination, said Griffin. They would be another tool to fight Covid. "It's nice to have another option," he said.



One challenge in developing antiviral drugs quickly has been recruiting enough participants for the clinical trials, each of which needs to enroll many hundreds of people, said Dr. Elizabeth Duke, a Fred Hutch research associate overseeing its molnupiravir trial. Participants must be unvaccinated and enrolled in the trial within five days of a positive Covid test. Any given day, interns make 100 calls to newly Covid-positive people in the Seattle area—and most say no. "Just generally speaking, there's a lot of mistrust about the scientific process," Duke said. "And some of the people are saying kind of nasty things to the interns." If the antiviral pills prove effective, the next challenge will be ramping up a distribution system that can rush them to people as soon as they test positive. Griffin said it will take something akin to the program set up last year by UnitedHealthcare, which sped Tamiflu kits to 200,000 at-risk patients enrolled in the insurer's Medicare Advantage plans. Merck officials predicted the company could produce more than 10 million courses of therapy by the end of the year. Atea and Pfizer have not released similar estimates. Even more promising? Studies evaluating whether antivirals can prevent infection after exposure. "Think about that," said Duke, who is also overseeing a prophylactic trial. "You could give it to everyone in a household, or everyone in a school. Then we're talking about a return to, maybe, normal life." (Courtesy weforum.org)



# 瑞源保險專欄31 奧巴馬保險申請攻略



瑞源保險事務所的信任和支持。為了帮助大家節省申請時需要的时间，下面我們就來跟大家來分享一下申請奧巴馬保險時會用到的一些信息。如果您事先準備好這些信息，那麼申請保險的過程就會更有效率。

**主要申請人的信息**  
包括主要申請人的姓名和出生日期。

**申請人家庭成員的信息**  
家庭成員包括：

- 你的配偶
- 任何您作為受扶養人列入納稅申報表的人，無論是否和你生活在一起。

除了美國公民之外，在美國只有合法居留身份才符合申請奧巴馬醫保。申請人需要提供證明您在美國有合法居住權的移民局的文件。比如工卡，綠卡，有效簽證等。如果您有交聯邦所得稅，需要提供您的報稅信息作為您收入證明的參考。如果您的收入在一定的區間之內，您將獲得不同程度的保費補貼。詳情請諮詢專業保險顧問。特別是2022年收入的範圍和往年有很大不同。一般來說，奧巴馬保險市場將把下面的這些收入計算在您的收入之內：

- 您的W-2表格和工資單上所報告的工資和薪水
- 任何自雇或業務的淨收入
- 失業補償
- 社會保障金，包括殘疾金（但不包括補充保障收入 (SSI)）
- 贍養費
- 退休或養老金收入，包括大部分IRA或401k提款

● 投資收入，如股息或利息

● 租金收入

● 其他應稅收入

明年預估的家庭收入

您需要提供您的家庭的明年的預估收入。如果您不確定，可以做出最佳估計。如果你的收入有變化，或與您估計的不同，您將在報稅時完成保費補貼的多退少補。同樣的欲知詳情，請聯繫專業保險顧問。

今年的奧巴馬開放註冊期是2021年11月1日至2022年1月15日。如果在2021年12月15日前註冊，新的保險將會在2022年1月1日生效。如果在2021年12月16日至2022年1月15日之間註冊，新的保險將在2022年2月1日生效。

通過瑞源保險事務所申請奧巴馬保險不收取任何手續費，因為保費都是統一定價的，所以通過經驗豐富的代理申請是最明智快捷的選擇。我們公司代理奧巴馬保險多年，為了更好的服務於我們的客戶，我們每年都會花費大量的時間調查和研究市場上的保險計劃，所以我們熟知每個保險計劃的保險條例和所涵蓋的內容。

公司創始人張瑞女士擁有約20年的行業經驗，曾擔任美國知名保險公司副總多年，是美國醫療保險協會認證會員，長期護理保險認證專員和資深醫療保險專員，多年奧巴馬醫保精英獎獲得者。積極義務服務社區并長期舉辦知識類講座。張瑞女士直線電話：214-971-8026，微信個人號：12149718026，公司Email: INFO@BENEFONS.COM。公司在達拉斯和休斯頓均有辦公室，服務全德州居民。

# 李医生引进最新设备治疗下肢疼痛！第一次治疗\$49元Coupon！

（本報記者黃梅子）步入中年，不少人會發現膝關節靈活不比從前，患有膝關節炎（Osteoarthritis of the knee）的風險也隨著年紀大了而提高。膝關節炎由軟骨及其周圍細胞耗損而引發，屬於相當常見的人體老化疾病之一。膝關節炎病發是由關節細胞耗損程度和修復程度失去平衡而導致，症狀包括關節疼痛、僵硬和功能減弱。情況嚴重時，還需要手術治療。

還有一部分患者下肢疼痛是Lateral Patellar Compression Syndrome 髌骨外側壓縮綜合症。另有些患者是因為頸椎腰椎或坐骨神經引起的下肢疼痛。還有些患者是車禍後遺症，有些人在車禍過去幾年以後才感覺到身體各種疼痛。

總之，不管您是哪種原因引起的下肢疼，都要引起重視，積極做康復治療，不管是膝關節炎還是車禍後遺症，康復治療總是比動手術更保險。康復治療一定要在醫生的指導下進行，否則有可能使得病情惡化。Texas Spinal Care的李醫生引進最新的多功

能下肢牽引治療儀，帮您減輕疼痛，快速恢復健康！這個機器經過FDA批准，是目前最先進最有效的下肢疼痛治療儀，其組成包括固定裝置，放鬆裝置，牽張裝置，能刺激大腿內側肌群及穴位，可通經活絡，緩解肌肉痙攣，激活運動神經元，恢復下肢運動功能。李醫生還有儀器測試足底，電腦掃描足部定做康復鞋墊，能很大程度地緩解下肢疼痛以及行走困難。

我們首先來看一看膝關節炎的病因，常居潮濕、寒冷環境的人多有症狀，與溫度低，引起血運障礙有關。第二是體重因素，肥胖和粗壯體型的人中發病率較高。第三是年齡因素，從中年到老年，隨年齡增長，常發生關節軟骨退化性變，關節多年累積性勞損是重要因素。第四，營養不良也有可能致病，關節軟骨內沒有血管，其營養依靠從關節液中吸取。軟骨的修復是靠外層的軟骨細胞分裂繁殖和軟骨細胞分泌基質來完成的，由於營養和氧供應不足，影響到軟骨細胞的增殖時，就會導致軟骨基質減少，軟

骨新生不足而變軟弱，極易在負重部位發生磨損。

髌股關節綜合症占到了所有運動相關的膝關節問題的25-40%，在膝關節功能障礙與運動損傷中十分常見。髌股疼痛綜合症風險最大的人群是跑步者，騎自行車者，籃球運動員以及相關跑跳較多的愛好者到運動員，當然主要還是動作模式問題與過度不正確使用所引起，病症發作可能是由於慢性損傷或者單次急性損傷直接引起，症狀包括膝關節彌漫性疼痛和局部髌下疼痛。髌骨周圍和下方、膝蓋前部、膝蓋骨的內側邊緣經常有壓痛，髌骨周圍後方發生持續的鈍疼疼痛，運動後有時會出現腫脹。在上下山坡、上下樓梯、久坐起身時，髌股關節位置疼痛往往更嚴重。膝蓋彎曲時可能伴隨發出噼啪聲「關節噪音」，髌股關節綜合症往往伴隨著大腿肌肉「股四頭肌」的肌張力異常，髌骨周圍的圓圈性疼痛範圍，久坐後症狀加劇，無力疼痛伴有膝關節屈曲減少。髌骨與股骨組成髌股關節，髌骨關節

和我們的股關節共組成了我們身體上著名的——膝關節，而我們的髌股關節形成在髌骨和股骨遠端之間，可謂是在夾縫中成長。治療中最重要的第一步是避免使問題惡化的活動，并且及時休息，光顧讓「疼」而不去治療的人是打算坐輪椅過下半生？

我們的髌骨本身沒有血液和淋巴液供應，所以一旦損傷恢復會非常的緩慢，停止進一步的損害是十分必要的。

李醫生治療下肢疼痛，先用電腦掃描儀器掃描足部，帮您定制復健矯正鞋墊，能极大地緩解走路時的疼痛，然後再用下肢牽引治療儀來復健治療，配合使用醫用去痛風濕乳液和營養素，是目前治療下肢疼痛的最佳治療組合。您攜帶這篇文章可以在第一次檢查和體驗治療時抵49元錢。

李醫生還專精車禍後的復健，車禍後PI與PIP都收。請打電話給李醫生免費諮詢。中文請與queen 陳 聯系。Texas Spinal care 電話：713-278-2225

網址：<http://txspinalcare.com>  
診所地址：2600 S Gessner RD, Suite 120, Houston, TX 77063  
診療時間：每週一至五全天，周六上午。



# 休斯顿动物园节日灯展正式开幕



休斯顿动物园节日灯展日前正式开幕，开幕仪式特别请到市长特纳出席参加并致词。还有各大主流媒体纷纷前来拍摄一年一度的美景。来宾们也在浓厚节日气氛下尽情的浏览共度美好时光。

